Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has announced a significant expansion of its ongoing ... Read More